Cypher Matthew

Director Cypher Matthew bought 1,420 shares of XRN at $35.12; 8 other insiders also bought within 14 days

Director Cypher Matthew purchased 1,420 shares at $35.12 on 2026-05-14, increasing his holdings from 270 shares to 1,690 shares. This transaction occurred while the stock is down 5.6% over 30 days and 11.3% from its 52-week high of $37.82, placing the purchase near the lower end of recent range. The timing aligns with a broader cluster pattern: 8 other insiders also bought within the past 14 days, representing coordinated open-market accumulation. Matthew's cross-ticker track record shows an average 90-day return of +330.3% with a 100.00% win rate across 1 prior buy, though this transaction represents his first purchase in XRN specifically and cannot be attributed to scheduled trading arrangements in the FACTS provided.

Director Matthew Cypher buys 1,350 shares of GMRE at $7.38 on 2025-08-26, first open-market purchase; stock trades at $37.35 (-26.5% from 52-week high).

Matthew Cypher, a director of Global Medical REIT Inc., purchased 1,350 shares at $7.38 on 2025-08-26, establishing an initial open-market position. The transaction occurred when the stock was trading at a significant discount to its 52-week high of $50.80, though the current price of $37.35 has recovered materially from the purchase price, representing positive performance over the holding period. GMRE's fundamentals show strained economics: quarterly revenue of $37,969,000.00 with net income of only $585,000.00, annual revenue contraction of -1.6%, and an extremely elevated P/E of 233.44, reflecting minimal profitability. The purchase of 1,350 shares for $9,960.44 represents a modest investment by a director with no prior open-market holdings in the company.